Related Experiment Video
Updated: Jun 17, 2025
Isolation of Regenerating Hepatocytes after Partial Hepatectomy in Mice
Published on: December 2, 2022
Cav3.2 deletion attenuates nonalcoholic fatty liver disease in mice
Xue Li1, Chengyun Hu1, Shanshan Luo1
1Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China; Departmentof Anesthesiology, Anhui Provincial Cancer Hospital. Hefei, Anhui 230031, China.
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and represents the main cause of liver cirrhosis and hepatocellular carcinoma. Cav3.2 is a T-type calcium channel that is widely present in tissues throughout the body and plays a vital role in energy and metabolic balance. However, the effects of Cav3.2 on the NFALD remain unclear. Here, we investigated the role of Cav3.2 channel in the development and progression of NAFLD. After 16 weeks on a high-fat diets (HFD), Cav3.2 knockout (Cav3.2 KO) improved hepatic steatosis, liver injury and metabolic syndrome in an NAFLD mouse model. We provided evidence that Cav3.2 KO inhibited HFD-induced hepatic oxidative stress, inflammation and hepatocyte apoptosis. In addition, Cav3.2 KO also attenuated hepatic lipid accumulation, oxidative stress, inflammation and hepatocyte apoptosis in palmitic acid/oleic acid (PAOA)-treated primary hepatocytes. These results suggest that therapeutic approaches targeting Cav3.2 provide effective approaches for treating NAFLD.
Insights
Targeting Cav3.2 T-type calcium channels may treat nonalcoholic fatty liver disease (NAFLD). Cav3.2 knockout mice showed improved liver health and reduced metabolic dysfunction in NAFLD models.
Area of Science:
- Cardiovascular Biology
- Metabolic Disorders
- Hepatology
Background:
- Nonalcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition, a leading cause of cirrhosis and liver cancer.
- Cav3.2 T-type calcium channels are crucial for metabolic and energy balance, but their role in NAFLD is not well understood.
Purpose of the Study:
- To investigate the role of Cav3.2 in the development and progression of NAFLD.
- To determine if targeting Cav3.2 could be a therapeutic strategy for NAFLD.
Main Methods:
- Utilized a high-fat diet (HFD) mouse model of NAFLD.
- Generated Cav3.2 knockout (Cav3.2 KO) mice for comparative analysis.
- Treated primary hepatocytes with palmitic acid/oleic acid (PAOA) to mimic NAFLD conditions in vitro.
Main Results:
- Cav3.2 KO significantly improved hepatic steatosis, liver injury, and metabolic syndrome in HFD-fed mice.
- Cav3.2 deficiency attenuated HFD-induced hepatic oxidative stress, inflammation, and hepatocyte apoptosis.
- Cav3.2 KO reduced lipid accumulation, oxidative stress, inflammation, and apoptosis in PAOA-treated hepatocytes.
Conclusions:
- Cav3.2 plays a significant role in the pathogenesis of NAFLD.
- Targeting Cav3.2 presents a promising therapeutic avenue for managing NAFLD and its associated complications.
